scholarly journals Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease

2012 ◽  
Vol 14 (3) ◽  
pp. R99 ◽  
Author(s):  
Sunao Sugita ◽  
Yuko Kawazoe ◽  
Ayano Imai ◽  
Yukiko Yamada ◽  
Shintaro Horie ◽  
...  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ya-Chiao Hu ◽  
Yao-Hsu Yang ◽  
Yu-Tsan Lin ◽  
Li-Chieh Wang ◽  
Hsin-Hui Yu ◽  
...  

2007 ◽  
Vol 245 (11) ◽  
pp. 1617-1621 ◽  
Author(s):  
Lothar Krause ◽  
Andreas Altenburg ◽  
Nikolaos E. Bechrakis ◽  
Gregor Willerding ◽  
Christos C. Zouboulis ◽  
...  

2015 ◽  
Vol 62 ◽  
pp. 67-74 ◽  
Author(s):  
H. Vallet ◽  
S. Riviere ◽  
A. Sanna ◽  
A. Deroux ◽  
G. Moulis ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Esra Guney ◽  
Gulunay Akcali ◽  
Betul Ilkay Akcay ◽  
Cihan Unlu ◽  
Gurkan Erdogan ◽  
...  

Behçet’s disease (BD) and vitiligo are diseases of unknown etiology. Interferon (IFN) alpha therapy is commonly used in Behçet uveitis. Interferon treatment in various diseases have also been observed causing certain autoimmune diseases such as vitiligo because of its immunomodulatory activity. The association between IFN therapy and vitiligo has been reported in the literature. We report a 21-year-old man with BD in whom vitiligo occurred during IFN treatment. To the best of our knowledge, this is the first reported case of such an association.


2012 ◽  
Vol 90 ◽  
pp. 0-0
Author(s):  
D GUINDOLET ◽  
D SAADOUN ◽  
N CASSOUX ◽  
C FARDEAU ◽  
V TOUITOU ◽  
...  

2017 ◽  
Vol 38 (1) ◽  
pp. 25-35 ◽  
Author(s):  
Jurgen Sota ◽  
Donato Rigante ◽  
Giuseppe Lopalco ◽  
Bruno Frediani ◽  
Rossella Franceschini ◽  
...  

1991 ◽  
Vol 66 (03) ◽  
pp. 292-294 ◽  
Author(s):  
K K Hampton ◽  
M A Chamberlain ◽  
D K Menon ◽  
J A Davies

SummaryCoagulation and fibrinolytic activities were studied in 18 subjects with Behçet's disease and compared with results from 14 matched control patients suffering from sero-negative arthritis. Significantly higher plasma concentrations (median and range) were found in Behçet's patients for the following variables: fibrinogen 3.7 (1.7-6.9) vs 3.0 (2.0-5.1) g/1, p <0.05; von Willebrand factor antigen, 115 (72-344) vs 74 (60-119)%, p <0.002; plasminogen activator activity (106/ECLT2) 219 (94-329) vs 137 (78-197) units, p <0.002; tissue plasminogen activator inhibitor (t-PA-I) activity, 9.1 (5.5-19.3) vs 5.1 (1.8-12.0) IU/ml, p <0.002; and PAI-1 antigen, 13.9 (4.5-20.9) vs 6.4 (2.4-11.1) ng/ml, p <0.002. Protein C antigen was significantly lower: 97 (70-183) vs 126 (96-220)%, p <0.02. No differences were observed in antithrombin III activity or antigen, factor VIII coagulant activity, fibrinopeptides A and Bβ15-42, plasminogen, α-2-antiplasmin, functional and immunological tissue-plasminogen activator, thrombin-antithrombin complexes and D-dimer. Levels of tissue plasminogen activator inhibitor (activity and antigen) correlated with disease activity while fibrinogen and von Willebrand factor concentrations did not. Seven of the 18 subjects with Behçet's disease had suffered thrombotic events but it was not possible to distinguish these from the 11 patients without thrombosis using the assays performed. The results suggest the abnormal fibrinolytic activity in Behçet's disease is due to increased inhibition of tissue plasminogen activator. No abnormality of coagulation or fibrinolytic activity specific to Behçet's disease was detected.


Sign in / Sign up

Export Citation Format

Share Document